# Pharmacogenomic and Pharmacoepigenomic Studies of Antipsychotic Drugs in First-Episode Schizophrenia

> **NCT07102069** · — · COMPLETED · sponsor: **Tianjin Anding Hospital** · enrollment: 384 (actual)

## Conditions studied

- Schizophrenia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07102069
- **Lead sponsor:** Tianjin Anding Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-01
- **Primary completion:** 2022-06-14
- **Final completion:** 2022-09-14
- **Target enrollment:** 384 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102069, "Pharmacogenomic and Pharmacoepigenomic Studies of Antipsychotic Drugs in First-Episode Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07102069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*